Solving Chronic Inflammation

Inhibiting the activity of the
NLRP3 inflammasome

We Target Chronic Inflammation

Recognizing the link between inflammation and numerous chronic diseases, Halia is pioneering targeting a specific inflammatory pathway, NLRP3, with an allosteric inhibitor to disrupt chronic inflammation. The goal of this method is to reduce inflammation and help reset this inflammatory pathway, potentially treating neurodegeneration and inflammatory diseases to improve quality of life and promote longevity.

Obesity

Almost half of US adults are obese or severely obese. Lack of physical activity, unhealthy eating behavior, and, in some cases, genetics contribute to obesity. Halia is developing investigational treatments to combat obesity.

Learn More

Pain and Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is an autoimmune condition where the immune system—normally the body's defender against infection and disease—attacks its own tissues. This results in pain, swelling, stiffness, and loss of joint function. Halia is developing an investigational treatment for both RA and post-surgical pain.

Learn More

Alzheimer's Disease

Alzheimer’s disease involves parts of the brain that control memory, language, problem-solving, and other thinking abilities. It can seriously affect a person’s ability to carry out daily activities. Halia is developing a potentially relevant pathway and investigational treatment for Alzheimer’s.

Learn More

Parkinson's Disease

Parkinson’s disease is a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves. Tremors, stiffness, or slowing of movement are typical symptoms. Halia is developing a potential brain-penetrant compound to treat the disease.

Learn More

Cancer

Cancer occurs when normal cells become cancerous cells that multiply and spread. Cancer is the second most common cause of death in the U.S. However, fewer people die of cancer now than 20 years ago19. Halia is developing potential pathways to prevent the onset of cancer.
Learn More
Kayakers - Chronic Inflammation

Live Better, Longer

We recognize that patients want to improve their health. Halia is dedicated to disrupting chronic inflammation to treat or prevent neurodegeneration and inflammatory diseases to improve quality of life and promote longevity.

NLRP3 Inflammasome:

Our drug targets to disrupt
chronic inflammation

Inflammation is an essential biological response of the human immune system that protects against disease. However, when dysregulated, inflammation can become a driver of disease by promoting a persistent, systemic immune response that fuels the development of many chronic diseases.1

One of the primary mechanisms mediating the persistent, systemic inflammatory response is activating a large protein complex called the NLRP3 inflammasome. The inflammasome activation produces pro-inflammatory signaling proteins, which contribute considerably to disease-causing inflammation.2

 

 

 

 

 

 

 

 

 

Pickleball Players

Science for longevity and quality of life

Our founders are renowned scientists with experience in drug discovery for oncology and neurodegeneration. We have made fundamental discoveries, identifying drug candidates that may potentially treat multiple disorders, including Alzheimer’s disease and other neurodegenerative disorders, as well as cancers and obesity.

Woman Doing Yoga

Be a part of health history:

Schedule an Appointment

Schedule a meeting

Contact Us

Contact us

Schedule an Appointment

Participate in a trial

In the News

Targeted Oncology – HT-6184 Advances to Second Stage of Phase 2 Trial in LR-MDS

Positive topline data from a phase 2 trial show HT-6184, an allosteric NEK7/NLRP3 inflammasome inhibitor, improves hematologic response in lower-risk MDS. Jordyn Sava December 17, 2024 The second stage of a phase 2 trial exploring the first-in-class allosteric NEK7/NLRP3 inflammasome inhibitor HT-6184 for the treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS) is launching...

read more

Longevity Technology – Promising data from Phase 2 study in myelodysplastic syndrome has potential implications for wider application in age-related diseases

Read this article on the website US biotech Halia Therapeutics has announced promising topline findings from its ongoing Phase 2 clinical trial of its oral treatment for lower-risk myelodysplastic syndromes. The drug, HT-6184, targets the NEK7 protein, which is critical to the activation of the NLRP3 inflammasome, a protein complex that drives inflammatory responses implicated in many...

read more

EndPoints News – Halia Therapeutics takes NLRP3 inhibitor into final stage of Phase 2 trial

Read this article on the website Halia Therapeutics is moving its lead asset into the second part of a mid-stage trial following initialpositive data in patients with an early form of blood cancer that affects the bone marrow. The Utah-based biotech is investigating its oral NEK7/NLRP3 inflammasome inhibitor, dubbedHT-6184, in patients with lower-risk myelodysplastic syndromes. Patients with MDS...

read more